Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL191421 | 1.00 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL29508771 | 1.00 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL5013207 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL31674399 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL503900 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL407991 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL1292751 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL664840 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL2289472 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL7515818 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115177543-B | Antibacterial caries preventing composition containing L-lactate, oral care product and preparation method and application thereof | 重庆登康口腔护理用品股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-20250059486-A1 | CELL-CONTROLLED PERFUSION IN CONTINUOUS CULTURE | BOEHRINGER INGELHEIM INT (DE) | 2025-02-20 | — | — | US | disclosed |
| US-12173267-B2 | Cell-controlled perfusion in continuous culture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-24 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| CN-115177543-B | Antibacterial caries preventing composition containing L-lactate, oral care product and preparation method and application thereof | 重庆登康口腔护理用品股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230242857-A1 | CELL-CONTROLLED PERFUSION IN CONTINUOUS CULTURE | BOEHRINGER INGELHEIM INT (DE) | 2023-08-03 | — | — | US | disclosed |
| EP-4148121-A2 | CELL-CONTROLLED PERFUSION IN CONTINUOUS CULTURE | Boehringer Ingelheim International GmbH (DE) | 2023-03-15 | — | — | EP | disclosed |
| US-11597903-B2 | Cell-controlled perfusion in continuous culture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-03-07 | — | — | US | disclosed |
| CN-115177543-A | Antibacterial and anticarious composition containing L-lactate, oral care product and preparation method and application thereof | 重庆登康口腔护理用品股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3303558-B1 | CELL-CONTROLLED PERFUSION IN CONTINUOUS CULTURE | BOEHRINGER INGELHEIM INT (DE) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | TP53 4492/4885CA1 1475/4885CA4 1858/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | TP53 4492/4885CA1 1475/4885CA4 1858/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | TP53 4492/4885CA1 1475/4885CA4 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.